Items where authors include "Brown, E"

Article

Wang, JYT orcid.org/0000-0002-3361-6413, Wu, Z, Kang, Y et al. (4 more authors) (2023) Walking school bus line routing for efficiency, health and walkability: A multi-objective optimisation approach. Journal of Multi-Criteria Decision Analysis, 30 (3-4). pp. 109-131. ISSN 1057-9214

Aalbers, J, AbdusSalam, SS, Abe, K et al. (598 more authors) (2023) A next-generation liquid xenon observatory for dark matter and neutrino physics. Journal of Physics G: Nuclear and Particle Physics, 50 (1). 013001. ISSN 0954-3899

Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736

Niemi, MEK, Karjalainen, J, Liao, RG et al. (3763 more authors) (2021) Mapping the human genetic architecture of COVID-19. Nature, 600 (7889). pp. 472-477. ISSN 0028-0836

Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X

Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X

Brown, E, Wilton, MM, Sprung, VS et al. (9 more authors) (2021) A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ Open, 11 (7). e045663. ISSN 2044-6055

Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Hurst, H, Jones, E, Ormandy, P et al. (11 more authors) (2021) Outcomes and care priorities for older people living with frailty and advanced chronic kidney disease: a multiprofessional scoping review protocol. BMJ Open, 11 (3). e040715. ISSN 2044-6055

Galdos, MV orcid.org/0000-0002-6080-0726, Brown, E, Rosolem, CA et al. (3 more authors) (2020) Brachiaria species influence nitrate transport in soil by modifying soil structure with their root system. Scientific Reports, 10 (1). 5072. ISSN 2045-2322

Shaw, J, Gosein, R, Kalita, MM et al. (19 more authors) (2020) Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy. eLife, 9. e52555.

Lee, MJ, Drake, TM, Sayers, AE et al. (532 more authors) (2020) Outcomes of obstructed abdominal wall hernia: results from the UK national small bowel obstruction audit. BJS Open, 4 (5). pp. 924-934. ISSN 2474-9842

Drake, TM, Lee, MJ orcid.org/0000-0001-9971-1635, Sayers, AE et al. (533 more authors) (2019) Outcomes following small bowel obstruction due to malignancy in the national audit of small bowel obstruction. European Journal of Surgical Oncology, 45 (12). pp. 2319-2324. ISSN 0748-7983

Darling, ES, McClanahan, TR, Maina, J et al. (77 more authors) (2019) Social–environmental drivers inform strategic management of coral reefs in the Anthropocene. Nature Ecology and Evolution, 3. pp. 1341-1350.

Baird, AJ orcid.org/0000-0001-8198-3229, Green, SM, Brown, E et al. (1 more author) (2019) Modelling time-integrated fluxes of CO2 and CH4 in peatlands: A review. Mires and Peat, 24. 16. ISSN 1819-754X

Dennis, M, Mead, G, Forbes, J et al. (1294 more authors) (2019) Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. The Lancet, 393 (10168). pp. 265-274. ISSN 0140-6736

Herrick, AL, Peytrignet, S, Lunt, M et al. (29 more authors) (2018) Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European scleroderma observational study. Annals of the Rheumatic Diseases, 77 (4). pp. 563-570. ISSN 0003-4967

Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253

Peytrignet, S, Denton, CP, Lunt, M et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324

Herrick, AL, Pan, X, Peytrignet, S et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 76 (7). pp. 1207-1218. ISSN 0003-4967

Haggard, MP, Gannon, MM, Birkin, JA et al. (140 more authors) (2012) Adjuvant adenoidectomy in persistent bilateral otitis media with effusion: hearing and revision surgery outcomes through 2 years in the TARGET randomised trial. Clinical Otolaryngology, 37 (2). 107 - 116. ISSN 1749-4478

Brown, E, Hurlow, A, Rahman, A et al. (2 more authors) (2010) Assessment of Fatigue after Blood Transfusion in Palliative Care Patients: A Feasibility Study. Journal of Palliative Medicine, 13 (11). 1327 - 1330 . ISSN 1096-6218

Conference or Workshop Item

Adams, R, Fisher, D, Graham, J et al. (13 more authors) (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. In: 2021 ASCO Annual Meeting I, 04-08 Jun 2021, Online.

Proceedings Paper

Richman, SD orcid.org/0000-0003-3993-5041, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .